These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16753371)

  • 1. Are bone scans necessary in men with low prostate specific antigen levels following localized therapy?
    Warren KS; Chodak GW; See WA; Iverson P; McLeod D; Wirth M; Morris C; Armstrong J
    J Urol; 2006 Jul; 176(1):70-3; discussion 73-4. PubMed ID: 16753371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program.
    Iversen P; Wirth MP; See WA; McLeod DG; Klimberg I; Gleason D; Chodak G; Montie J; Tyrrell C; Wallace DM; Delaere KP; Lundmo P; Tammela TL; Johansson JE; Morris T; Carroll K;
    Urology; 2004 May; 63(5):928-33. PubMed ID: 15134983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy.
    Loeb S; Makarov DV; Schaeffer EM; Humphreys EB; Walsh PC
    J Urol; 2010 Jul; 184(1):157-61. PubMed ID: 20483148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.
    McLeod DG; Iversen P; See WA; Morris T; Armstrong J; Wirth MP;
    BJU Int; 2006 Feb; 97(2):247-54. PubMed ID: 16430622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of bicalutamide in adjuvant treatment of prostatic carcinoma after primary therapy with curative aim. The viewpoint of the surgeon].
    Rigatti P; Scattoni V
    Recenti Prog Med; 2002 Mar; 93(3):183-5. PubMed ID: 11942171
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bicalutamide: in early-stage prostate cancer.
    Carswell CI; Figgitt DP
    Drugs; 2002; 62(17):2471-79; discussion 2480-1. PubMed ID: 12421104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.
    See WA; Wirth MP; McLeod DG; Iversen P; Klimberg I; Gleason D; Chodak G; Montie J; Tyrrell C; Wallace DM; Delaere KP; Vaage S; Tammela TL; Lukkarinen O; Persson BE; Carroll K; Kolvenbag GJ;
    J Urol; 2002 Aug; 168(2):429-35. PubMed ID: 12131282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Locally advanced prostate cancer: definition, prognosis and treatment].
    Plantade A; Massard C; de Crevoisier R; Fizazi K
    Bull Cancer; 2007 Jul; 94(7 Suppl):F50-61. PubMed ID: 17845994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levels of alpha 2 macroglobulin can predict bone metastases in prostate cancer.
    Kanoh Y; Ohtani N; Mashiko T; Ohtani S; Nishikawa T; Egawa S; Baba S; Ohtani H
    Anticancer Res; 2001; 21(1B):551-6. PubMed ID: 11299802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
    Di Lorenzo G; Perdonà S; De Placido S; D'Armiento M; Gallo A; Damiano R; Pingitore D; Gallo L; De Sio M; Autorino R
    J Urol; 2005 Dec; 174(6):2197-203. PubMed ID: 16280763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant hormonal treatment - the bicalutamide early prostate cancer program.
    Wirth MP; Hakenberg OW; Froehner M
    Front Radiat Ther Oncol; 2008; 41():39-48. PubMed ID: 18544984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
    Tsai HK; Chen MH; McLeod DG; Carroll PR; Richie JP; D'Amico AV
    Cancer; 2006 Dec; 107(11):2597-603. PubMed ID: 17039498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Adjuvant treatment of prostatic carcinoma after primary therapy. The "Early Prostate Cancer" Program].
    Mansueto G; Longo F
    Recenti Prog Med; 2002 Mar; 93(3):175-8. PubMed ID: 11942169
    [No Abstract]   [Full Text] [Related]  

  • 16. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N; Onishi T; Arima K; Sugimura Y
    Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Adjuvant hormone therapy in prostatic cancer: after treatment with curative intent. The viewpoint of the urologist].
    Martorana G
    Recenti Prog Med; 2002 Mar; 93(3):179-82. PubMed ID: 11942170
    [No Abstract]   [Full Text] [Related]  

  • 19. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
    Lodde M; Lacombe L; Fradet Y
    Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer.
    See W; Iversen P; Wirth M; McLeod D; Garside L; Morris T
    Eur Urol; 2003 Nov; 44(5):512-7; discussion 517-8. PubMed ID: 14572747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.